Vertex’s Crinetics deal clears antitrust—only the shareholder vote remains

The merger clears its main regulatory checkpoint, but this is confirmation—not a surprise. The HSR waiting period expired on August 12, 2026, and required approvals in Austria, Germany and Australia were received by August 13, 2026, subject to Australia’s waiting period expiring on August 27. 〔0〕 Because the Vertex acquisition was already announced on July 6, the transaction’s direction was known; the new information is that the regulatory process is progressing without a disclosed obstacle. (Item 8.01)

The remaining path is now narrower, with shareholder approval as the key named condition. Crinetics still requires shareholder adoption at the special meeting scheduled for August 28, 2026, alongside the remaining closing conditions. 〔1〕 (Merger approval conditions)

The expected closing timeline is unchanged rather than accelerated. Assuming shareholder approval, the companies still expect the transaction to close in early September 2026. 〔2〕 Against the market’s standing expectation that an announced deal would seek routine antitrust clearance, this is an on-track update with neutral incremental information—not a clean positive surprise.